- BTCY recently announced a capital raise, leading to a sudden and significant decrease in the share price.
- With likely catalysts ahead, and continued stellar growth in its core business, the recent share price drop presents a compelling buying opportunity.
- In conjunction with the secondary offering, BTCY has now been uplisted to Nasdaq, providing more visibility and liquidity in the stock.
- Anapp currently under development by BTCY could blow the top off all current management guidance and analyst estimates.
- While there are certainly risks, the stock could conceivably double over the next year.
For further details see:
Biotricity: Capital Raise Leads To Buying Opportunity